Global Mesenchymal Stem Cells Market Report 2019: Annual Estimates & Forecasts 2015-2022

Global Mesenchymal Stem Cells Market Report 2019: Annual Estimates & Forecasts 2015-2022


DUBLIN, Feb. 13, 2019 /PRNewswire/ —

The “Mesenchymal Stem Cells – Market Analysis, Trends, and Forecasts” report has been added to’s offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Mesenchymal Stem Cells in US$ Million.

The report profiles 47 companies including many key and niche players such as:

  • Cell Applications, Inc. (USA)
  • Celprogen, Inc. (USA)
  • Cyagen US Inc. (USA)
  • Genlantis, Inc. (USA)
  • Lonza Group (Switzerland)
  • Mesoblast Limited (Australia)
  • MilliporeSigma (USA)
  • Neuromics (USA)
  • Orthofix International N.V. (Italy)
  • PromoCell GmbH (Germany)
  • R&D Systems, Inc. (USA)
  • ScienCell Research Laboratories (USA)
  • Stemcell Technologies Inc. (Canada)
  • Stemedica Cell Technologies, Inc. (USA)
  • Thermo Fischer Scientific, Inc. (USA)
  • Vitro Biopharma (USA)

Key Topics Covered:


Mesenchymal Stem Cells Market on a Rapid Growth Path
Current and Future Analysis
The Present and Future of MSC Therapies
Select MSC-based Therapeutics
Mesenchymal Stem Cell Research
Completed Phase III Studies with MSCs
MSCs are Being Explored for Several New Treatment Possibilities
Widespread Commercialization of ‘Off-the-Shelf’ MSCs to Become a Reality
Software Companies Endeavour to Cash in on the Boom

Development of Regenerative Medicine Accelerates Demand for MSCs
Ageing Demographics to Drive Demand for Mesenchymal Stem Cell Therapies
Global Aging Population Statistics – Opportunity Indicators
Growing Prevalence of Chronic Diseases Propels Demand for Mesenchymal Stem Cells
Key Disease Statistics – Opportunity Indicators
Growing Volume of Orthopedic Procedures: An Opportunity for the MSC Market
Adult Stem Cell Therapies on Growth Trajectory, as Controversies Continue to Haunt Embryonic Stem Cell Research
Adult Stem Cells and Embryonic Stem Cells – A Comparison
MSCs Versus Embryonic or Induced Pluripotent Stem Cells
MSC Therapies – Immune to Ethical Issues Applicable to Embryonic Stem Cells
MSCs – A Potential Vehicle for ‘Targeted Drug Delivery’
Stem Cell Based Bone Grafts: Promising Growth Ahead
Loopholes Associated with In Vivo Properties Constrain Therapeutic Advancements
Major Challenges Confronting Mesenchymal Stem Cell Market
Allogeneic MSCs – Offering Promise in Immunosuppressive and Tissue Repair Therapy
Administration Route Determines the Effectiveness of MSCs

Adult Stem Cells
A Low Risk Investment
Adult Stem Cells Garner More Investments for Research
Low Versatility – A Major Limiting Factor for Adult Stem Cells
Hematopoietic Stem Cells – Enjoying Enduring Success
Restraining Factors
Induced Pluripotent Stem Cells – An Alternative to ESCs
A Peek into the Discovery of iPS
Drug Development – A Major Application for iPS
Use of iPS for Regenerative Medicine
Establishing iPS Cell Banks
Intractable and Congenital Disease Treatments
Embryonic Stem Cells to Transfigure Medicine
Ethical Issues and Technical Hurdles Bog Down hESC Research
Lack of Safety and Efficacy Data – A Key Concern

Mesenchymal Stem Cells in Orthopedics
MSC based Models for Orthopedic Repair
Delivery of MSCs to Regions Requiring Therapy
MSCs in the Treatment of Osteoarthritis
MSCs in the Treatment of Rheumatoid Arthritis
MSCs in Cancer Treatment
MSCs in Hepatology
MSCs in Neurology
MSCs in Cardiology
MSCs in Radiotherapy
MSCs in the Treatment of Diabetes
MSCs in the Treatment of Autoimmune Diseases
MSCs in Treatment of Premature Ovarian Failure
MSCs for Gene Therapy
MSC Therapy in the Treatment of Lung Diseases
MSCs for Treating Liver Disease
MSCs for Treating Multiple Sclerosis-Phase II Clinical Trial Completed in the US (2016)
MSCs in Colon Repair
MSCs in Kidney Repair

Mesenchymal Stem Cells (MSCs) – An Introduction
What Are Allogeneic Mesenchymal Stem Cells?
Some Major Sources of Mesenchymal Stem Cells
Bone Marrow
Wharton’s Jelly and Umbilical Cord Blood
Adipose Tissue
Trophoblastic Tissues
Amniotic Fluid
Developing Tooth Bud of Mandibular Third Molar
Mechanism of Mesenchymal Stem Cell Therapy
Important Features of Mesenchymal Stem Cells
Differentiation Capacity
Immuno-modulatory Effects
Clinical Use
Production of Clinical-Grade MSCs
Drawbacks of MSCs


7.1 Focus on Select Players

7.2 Product Launches
RoosterBio Launches CliniControl (CC) Product Portfolio
Provia Labs Launches Library of Stem Cell Material Available for Researchers
JCR Pharmaceuticals Develops TEMCELL HS
PuRec Announces Plans to Produce MSCs/RECs

7.3 Recent Industry Activity
Mesoblast Partners with Tasly for MPC Products
SanBio Acquires Patent Portfolio Regarding Cell Medicines Derived from MSC
Otsuka to Acquire New Shares Issued by TWO CELLS
Stemedica Receives FDA Approval for Phase Iia Clinical Study for Traumatic Brain Injury
Stemedica Enrolls into Phase I/IIa Clinical Study for Ischemic Stroke



9.1 The United States
A. Market Analysis
Rapidly Ageing Population: A Major Driving Demand for MSC based Therapies
Increasing Incidence of Chronic Diseases Drives Focus onto MSCs
Prochymal Obtains Fast Track Designation from FDA
MSCs for Treating Multiple Sclerosis-Phase II Clinical Trial Completed in the US
Rising Governmental Investments in Stem Cell Therapies – A Growth Booster
FDA Issues Warning Against Illegal Stem Cell Therapies
US Regulates Stem Cells as Drugs
Federal Law on Stem Cells in the US
NIH at the Forefront of Research Funding
NIH Guidelines on Stem Cell Research Funding
Bans and Restrictions on Stem Cell Research
American Type Culture Collection Inc (ATCC) – A Major Non-Profit Organization
B. Market Analytics

9.2 Canada
A. Market Analysis
Current and Future Analysis
Prochymal – Canada’s First MSC-based Therapy
B. Market Analytics

9.3 Japan
Current and Future Analysis
Increasing Demand for Regenerative Medicine in Geriatric Healthcare and Cancer Care to Drive Demand for Mesenchymal Stem Cells
New Regulation for Accelerated Stem Cell Approval and Its Impact on Stem Cells Product Market

9.4 Europe
Ageing Population to Drive Demand for MSC based Therapies
Cancer in Europe: Key Statistics
Legislations on Stem Cell Research and Therapy in the EU
Unproven Stem Cell Therapies Receive Government Backing in the EU?
Scientists and Government Tussle over Safety of Stamina Foundation’s MSC Therapy in Italy
Stem Cell Clinics Shut Down in Germany due to Malpractices

9.5 Asia-Pacific
ACurrent and Future Analysis
Overview of Select Countries
Stem Cell Tourism – A Popular Trend in Australia
South Korea
South Korea Pacing towards Regaining Lost Glory in Stem Cell Research
South Korea Upbeat on Stem Cell Therapy Market Potential
An Outline of the Stem Cell Research Structure in India
A Regulatory Picture of the Indian Stem Cell Research and Therapy
Adult Stem Cells – A Highly Money-Spinning Market
Indians ‘Bank’ on Dental Stem Cells
New Zealand
Stem Cell Research Scenario in New Zealand

9.6 Rest of World
A. Market Analysis
Current and Future Analysis
Stem Cell Research in Full Swing in Israel


Total Companies Profiled: 47

  • The United States (25)
  • Canada (1)
  • Japan (2)
  • Europe (6)
    • Germany (2)
    • The United Kingdom (1)
    • Rest of Europe (3)
  • Asia-Pacific (Excluding Japan) (9)
  • Latin America (1)
  • Middle East (3)

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links


Source link Google News